Better Therapeutics, Inc. financial data

Location
548 Market St. #49404, San Francisco, CA
State of incorporation
DE
Fiscal year end
December 31
Former names
Mountain Crest Acquisition Corp II (to 10/28/2021)
Latest financial report
10-Q - Q3 2023 - Nov 9, 2023

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 77.2 % -86.5%
Debt-to-equity -285 % -479%
Return On Equity 401 %
Return On Assets -217 % -89.6%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 47.4M shares +99.6%
Common Stock, Shares, Outstanding 40.6M shares +70.9%
Entity Public Float 15.3M USD -75%
Common Stock, Value, Issued 4K USD +100%
Weighted Average Number of Shares Outstanding, Basic 38.5M shares +62.5%
Weighted Average Number of Shares Outstanding, Diluted 38.5M shares +62.5%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 10.5M USD -46.8%
Selling and Marketing Expense 6.9M USD +6.72%
General and Administrative Expense 12.2M USD -22.9%
Operating Income (Loss) -29.6M USD +29.6%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -31.6M USD +29.7%
Income Tax Expense (Benefit) 3K USD 0%
Net Income (Loss) Attributable to Parent -31.6M USD +29.7%
Earnings Per Share, Basic -1.16 USD/shares +68.8%
Earnings Per Share, Diluted -1.16 USD/shares +68.8%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 6.6M USD -70.4%
Other Assets, Current 73K USD +17.7%
Assets, Current 7.35M USD -68.7%
Property, Plant and Equipment, Net 102K USD -16.4%
Other Assets, Noncurrent 483K USD -1.03%
Assets 10.7M USD -62%
Accounts Payable, Current 2.31M USD +83.9%
Employee-related Liabilities, Current 1.89M USD -23.9%
Liabilities, Current 12.9M USD +38.9%
Liabilities 20.7M USD -1.48%
Retained Earnings (Accumulated Deficit) -134M USD -30.7%
Stockholders' Equity Attributable to Parent -9.94M USD -237%
Liabilities and Equity 10.7M USD -62%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -13.8M USD -55.8%
Net Cash Provided by (Used in) Financing Activities -435K USD -43600%
Net Cash Provided by (Used in) Investing Activities -521K USD -1236%
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 40.6M shares +70.9%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -9.67M USD -8.76%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 6.6M USD -70.4%
Interest Paid, Excluding Capitalized Interest, Operating Activities 495K USD +126%
Deferred Tax Assets, Valuation Allowance 14.7M USD +132%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 15.5M USD +109%
Payments to Acquire Property, Plant, and Equipment 26K USD -33.3%
Property, Plant and Equipment, Gross 178K USD -42.6%
Unrecognized Tax Benefits 77K USD 0%
Depreciation, Depletion and Amortization 755K USD +13.9%
Deferred Tax Assets, Net of Valuation Allowance 822K USD -23%
Share-based Payment Arrangement, Expense 423K USD +15.6%
Interest Expense 1.95M USD +27.6%